Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Organisation › Details

Probiodrug (Group)

Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease. Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions. Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research. *

 

Period Start 1997-06-01 established
Products Industry drug development technology
  Industry 2 QC inhibitor (glutam(in)yl cyclase inhibitor)
Persons Person Dauer, Ulrich (Probiodrug 201805– CEO before Omeicos + Activaero + 4SC + Tripos)
  Person 2 Schäffer, Michael (Probiodrug 201810– CBO joined 201808 as EVP Business + Strategy before Crelux + Sireen)
     
Region Region Halle (Saale)
  Country Germany
  Street 22 Weinbergweg
  City 06120 Halle (Saale)
  Tel +49-345-55599-00
    Address record changed: 2018-07-24
     
Basic data Employees B: 11 to 50 (2016-12-31)
  Currency EUR
  Annual sales 44,000 (operating income (2015) 2015-12-31)
  Profit -13,891,000 (2016-12-31)
  Cash 9,300,000 (2018-03-31)
     
    * Document for �About Section�: Probiodrug AG. (10/7/15). "Press Release: Probiodrug Signs Agreement with Rentschler for Manufacture of Its pGlu-Abeta Targeting Antibody PBD-C06". Halle/Saale & Laupheim.
     
   
Record changed: 2018-10-07

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for Probiodrug (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px




» top